Tech Company Financing Transactions
Inviragen Funding Round
On 3/31/2012, Inviragen landed $5.5 million in funding from Bio*One Capital, CLS and Venture Investors.
Transaction Overview
Company Name
Announced On
3/31/2012
Transaction Type
Venture Equity
Amount
$5,454,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
1613 Prospect Pkwy. 100
Fort Collins, CO 80525
USA
Fort Collins, CO 80525
USA
Phone
Website
Email Address
Overview
Inviragen, Inc. is committed to developing safe, effective vaccines to address this need. Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dan Stinchcomb
Chief Medical Officer
Gilad Gordon
Chief Operating Officer
Joseph Santangelo
Chief Scientific Officer
Jorge Osorio
Browse more venture capital transactions:
Prev: 3/31/2012: Zift Solutions venture capital transaction
Next: 3/31/2012: Microfabrica venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here come from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs